Impact of the Central Blood Pressure Level in Cerebral Metabolic Aging: a 18F-FDG PET Study.

NCT ID: NCT03345290

Last Updated: 2022-08-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 92 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-07-31
• Study Completion Date: 2020-11-06

Brief Summary

Cerebral glycolytic metabolism can be quantified by quantitative analysis of 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET). This allows to identify neurological diseases at an early stage of functional abnormalities, before any anatomical lesions, and to differentiate them from the "normal" brain aging. Aging mainly leads to atrophy with a decrease in cerebral metabolism in the prefrontal cortex, with consequent deterioration of cognitive processes, in particular executive functions (5).

In a population of 92 "control" subjects, investigators have already quantified the importance of the aging in frontal cortex hypometabolism. These patients were referred for a 18F-FDG PET in the follow-up of lymphoma considered to be in complete remission (PET without cerebral step), without any chemoradiotherapy within 2 months and with normal neuropsychological tests (Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Battery FAB).

However, cerebral aging can be "accelerated" by vascular risk factors, including increased central blood pressure, as investigators have recently reported in a pilot study involving elderly patients. This central pressure, which is directly linked to the cerebral micro-vascularization, can be easily measured by applanation tonometry. In this pilot study, investigators showed that a central pulse pressure equal or greater than 50 mmHg was associated with a significant frontal hypometabolism in elderly patients. This confirmed, at a stage of pre-clinical remodeling, the worse prognostic significance for this criterion, as reported in large epidemiological studies (increased risk of stroke and cardiac vascular events).

However, it is not yet known whether the level of central blood pressure interfere with the brain metabolism of younger subjects, especially with regard to aging observed throughout life. If this hypothesis is confirmed, preventive therapeutic strategies for accelerated aging, could thus integrate the monitoring of central pressure and cerebral metabolism.

The objective of this study is to determine, in a population of control subjects and on a larger scale, the impact of central blood pressure on brain metabolic aging , by using 18F-FDG PET.

Conditions

Aging Disorder

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Subjects

Subjects referred to a FDG PET scan (standard PET without cerebral step) without any oncologic setting. Patients will be included as following critera: 25% of subjects will have under 40 years old, 25% between 40 and 60 yeard old et 50% higher than 60 years old.

Group Type: EXPERIMENTAL

PET with a cerebral step

Intervention Type: DEVICE

Positron Emission Tomography with a cerebral step before to carry out the standard Position Emission Tomography

Central blood pressure measurement

Intervention Type: DEVICE

Central blood pressure measurement

Neurocognitive tests

Intervention Type: OTHER

Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Batery FAB

Interventions

PET with a cerebral step

Positron Emission Tomography with a cerebral step before to carry out the standard Position Emission Tomography

Intervention Type: DEVICE

Central blood pressure measurement

Central blood pressure measurement

Intervention Type: DEVICE

Neurocognitive tests

Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Batery FAB

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• > 18 years old, with written informed consent,
• Subjects referred for 18F-FDG PET in a non-oncological setting,
• Absence of pregnancy or breastfeeding,
• Lack of chemotherapy in the previous year and no cerebral radiotherapy.
• No history of psychiatric or neurological pathology.
• Absence of treatment with psychotropic action, and absence of corticosteroids.

Exclusion Criteria

• "abnormal" neuropsychological tests:

• Mini Mental State Examination (MMSE) <27,
• Current major depressive episode on the Mini International Neuropsychologic Interview (MINI),
• Frontal Assessment Battery (FAB) <15.
• 18F-FDG PET examination showing ischemic, neurodegenerative, neoplastic or other brain lesions (independent of a normal or accelerated aging process).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Central Hospital, Nancy, France

OTHER

Sponsor Role: lead

Responsible Party

Antoine VERGER

MD, PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Antoine Verger, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

CHRU Nancy

Locations

CHRU Nancy

Vandœuvre-lès-Nancy, , France

Countries

France

References

Hurstel M, Joly L, Imbert L, Zimmermann G, Roch V, Schoepfer P, Lamiral Z, Salvi P, Benetos A, Verger A, Marie PY. Volume of the proximal half of the thoracic aorta is the most comprehensive FDG-PET/CT indicator of arterial aging throughout adulthood. Eur J Hybrid Imaging. 2023 Jun 28;7(1):11. doi: 10.1186/s41824-023-00169-2.

Reference Type: DERIVED

PMID: 37369917 (View on PubMed)

Other Identifiers

PSS2016/PACTEP-VERGER/VS

Identifier Type: -

Identifier Source: org_study_id